Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Masked, Phase 1b Study Evaluating the Safety, Tolerability, and Dose-Response of Topical AG-80308 in Patients With Dry Eye Disease

NCT05372107 is registered in ClinicalTrials.gov with Allgenesis Biotherapeutics Inc. as lead sponsor.

NCT NCT05372107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05372107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Masked, Phase 1b Study Evaluating the Safety, Tolerability, and Dose-Response of Topical AG-80308 in Patients With Dry Eye Disease
Lead sponsor
Allgenesis Biotherapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2022
Completion date
November 2, 2022
Enrollment
84 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease